129 related articles for article (PubMed ID: 26091278)
1. Pharmacological treatment of 22q11.2 deletion syndrome-related psychoses.
Boot E; Butcher NJ; Vorstman JA; van Amelsvoort TA; Fung WL; Bassett AS
Pharmacopsychiatry; 2015 Sep; 48(6):219-20. PubMed ID: 26091278
[TBL] [Abstract][Full Text] [Related]
2. 22q11.2 deletion syndrome: atypical antipsychotics and relapsing psychoses.
Verhoeven WM; Egger JI
Pharmacopsychiatry; 2015 Sep; 48(6):220-1. PubMed ID: 26244857
[TBL] [Abstract][Full Text] [Related]
3. Atypical Antipsychotics and Relapsing Psychoses in 22q11.2 Deletion Syndrome: A Long-term Evaluation of 28 Patients.
Verhoeven WM; Egger JI
Pharmacopsychiatry; 2015 May; 48(3):104-10. PubMed ID: 25654302
[TBL] [Abstract][Full Text] [Related]
4. [Not Available].
Angelopoulos E; Theleritis C; Economou M; Georgatou K; Papageorgiou CC; Tsaltas E
Pharmacopsychiatry; 2017 Jul; 50(4):162-163. PubMed ID: 28511206
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and side effects of psychopharmacotherapy in individuals with 22q11.2 deletion syndrome with comorbid psychiatric disorders: a systematic review.
Mosheva M; Korotkin L; Gur RE; Weizman A; Gothelf D
Eur Child Adolesc Psychiatry; 2020 Aug; 29(8):1035-1048. PubMed ID: 30949827
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of clozapine in treatment-resistant psychotic patients with DiGeorge syndrome (22q11.2 deletion syndrome): a case series.
Berardelli I; Cifrodelli M; Giuliani C; Antonelli G; Putotto C; Pulvirenti F; Pompili M
Int Clin Psychopharmacol; 2024 Jul; 39(4):284-287. PubMed ID: 37824335
[TBL] [Abstract][Full Text] [Related]
7. The effectiveness and tolerability of pharmacotherapy for psychosis in 22q11.2 Deletion Syndrome: A systematic review.
Tanham M; Chen R; Warren N; Heussler H; Scott JG
Aust N Z J Psychiatry; 2024 May; 58(5):393-403. PubMed ID: 38383990
[TBL] [Abstract][Full Text] [Related]
8. Neuroimaging and clinical features in adults with a 22q11.2 deletion at risk of Parkinson's disease.
Butcher NJ; Marras C; Pondal M; Rusjan P; Boot E; Christopher L; Repetto GM; Fritsch R; Chow EWC; Masellis M; Strafella AP; Lang AE; Bassett AS
Brain; 2017 May; 140(5):1371-1383. PubMed ID: 28369257
[TBL] [Abstract][Full Text] [Related]
9. Cognitive behavioral therapy in 22q11.2 microdeletion with psychotic symptoms: What do we learn from schizophrenia?
Demily C; Franck N
Eur J Med Genet; 2016 Nov; 59(11):596-603. PubMed ID: 27639442
[TBL] [Abstract][Full Text] [Related]
10. [Graves disease and IgA deficiency as manifestations of 22q11.2 deletion syndrome].
Silva JM; Silva CP; Melo FF; Silva LA; Utagawa CY
Arq Bras Endocrinol Metabol; 2010 Aug; 54(6):572-7. PubMed ID: 20857064
[TBL] [Abstract][Full Text] [Related]
11. Update on the 22q11.2 deletion syndrome and its relevance to schizophrenia.
Van L; Boot E; Bassett AS
Curr Opin Psychiatry; 2017 May; 30(3):191-196. PubMed ID: 28230630
[TBL] [Abstract][Full Text] [Related]
12. [Neurocognitive and psychiatric management of the 22q11.2 deletion syndrome].
Demily C; Rossi M; Schneider M; Edery P; Leleu A; d'Amato T; Franck N; Eliez S
Encephale; 2015 Jun; 41(3):266-73. PubMed ID: 25523123
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of long-lasting psychosis in a case of 22q11.2 deletion syndrome.
Müller UJ; Fellgiebel A
Pharmacopsychiatry; 2008 Jul; 41(4):158-9. PubMed ID: 18651346
[No Abstract] [Full Text] [Related]
14. Predominant negative symptoms in 22q11.2 deletion syndrome and their associations with cognitive functioning and functional outcome.
Schneider M; Van der Linden M; Menghetti S; Glaser B; Debbané M; Eliez S
J Psychiatr Res; 2014 Jan; 48(1):86-93. PubMed ID: 24189154
[TBL] [Abstract][Full Text] [Related]
15. [Child psychiatry interventions in patients with 22q11 deletion syndrome: From treatment to prevention].
Novo A; Woestelandt L; Rousselot-Pailley B; Leitgel M; Eutrope J; Rio M; Lyonnet S; Robel L
Encephale; 2019 Apr; 45(2):175-181. PubMed ID: 30470499
[TBL] [Abstract][Full Text] [Related]
16. Referential communication abilities in children with 22q11.2 deletion syndrome.
Van Den Heuvel E; ReuterskiöLd C; Solot C; Manders E; Swillen A; Zink I
Int J Speech Lang Pathol; 2017 Oct; 19(5):490-502. PubMed ID: 27690637
[TBL] [Abstract][Full Text] [Related]
17. Using antipsychotic agents in older patients.
Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
[TBL] [Abstract][Full Text] [Related]
18. Lymphoproliferative disorder with polyautoimmunity and hypogammaglobulinemia: An unusual presentation of 22q11.2 deletion syndrome.
Soares DC; Dantas AG; Matta MC; Pastorino AC; Melaragno MI; Kulikowski L; Montenegro M; Kim CA; Carneiro-Sampaio M; Torres LC
Clin Immunol; 2020 Nov; 220():108590. PubMed ID: 32920211
[TBL] [Abstract][Full Text] [Related]
19. Risk factors and the evolution of psychosis in 22q11.2 deletion syndrome: a longitudinal 2-site study.
Gothelf D; Schneider M; Green T; Debbané M; Frisch A; Glaser B; Zilkha H; Schaer M; Weizman A; Eliez S
J Am Acad Child Adolesc Psychiatry; 2013 Nov; 52(11):1192-1203.e3. PubMed ID: 24157393
[TBL] [Abstract][Full Text] [Related]
20. The Effectiveness and Safety of Antipsychotic and Antidepressant Medications in Individuals with 22q11.2 Deletion Syndrome.
Dori N; Green T; Weizman A; Gothelf D
J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):83-90. PubMed ID: 26131914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
